Type IV hemochromatosis is associated with dominant mutations in the SLC40A1 gene encoding ferroportin (FPN). Known as the "ferroportin disease", this condition is typically characterized by high serum ferritin, reduced transferrin saturation and macrophage iron loading. Previously FPN expression in vitro has been shown to cause iron deficiency in human cell lines and mediate iron export from Xenopus oocytes. We confirm these findings by showing that expression of human FPN in a human cell line results in an iron deficiency due to a three-fold increased export of iron. We show that FPN mutations A77D, V162 and G490D that are associated with a typical pattern of disease in vivo cause a loss of iron export function in vitro,
Introduction
Hemochromatosis is an iron overload disease characterized by excessive iron uptake through the enterocytes of the gut, and subsequent deposition in the liver, spleen and heart leading to tissue damage. Currently four subtypes of hemochromatosis are recognized. In Caucasian populations disease is predominantly associated with mutations in the HFE gene, discovered in 1996 1 ; HFE-linked hemochromatosis is designated Type I. A more severe form of the disease, juvenile hemochromatosis (Type II hemochromatosis), is linked to mutations in either the recently identified hemojuvelin 2 or the antimicrobial peptide hepcidin 3, 4 . Hepcidin is normally upregulated in response to high serum iron, but is unexpectedly low in patients with hemochromatosis due to mutations in HFE 5 , Hemojuvelin 2 and Transferrin receptor-2 (TfR-2) 6, 7 . TfR-2 which is expressed by hepatocytes 8, 9 is mutated in hemochromatosis type III. The iron exporter ferroportin/IREG-1/MTP-1 (FPN, gene name SLC40A1) was discovered simultaneously by three groups [10] [11] [12] . Since this time, numerous mutations in the gene have been implicated in patients from diverse ethnic origins with previously unexplained hemochromatosis. Iron overload disease due to a mutation in FPN is referred to as Type IV hemochromatosis or ferroportin disease 13 . FPN is expressed on basolateral membranes of mature intestinal enterocytes and the basal membrane of the placental syncytiotrophoblast [10] [11] [12] .
Another site of high expression of FPN is in macrophages, including Kupffer cells in the liver and in the red pulp of the spleen 12, 14 . These sites of expression are consistent with a role for FPN in transport of iron from the gut to the serum, from the mother to the fetus and in iron recycling from effete red blood cells back into the serum.
HEK293T cells transfected with mouse Slc40a1 were shown to increase binding of iron regulated protein-1 to an iron response element (IRE), indicating a low cellular iron state, and the same cells were shown to be low in the iron storage protein ferritin 12 .
Studies expressing FPN in
Xenopus oocytes have shown that it mediates iron export, which may be enhanced in the presence of the multicopper-oxidase, ceruloplasmin 10 .
One of the groups that discovered FPN found that the weh zebrafish which exhibits severe microcytic anemia, had an L167F mutation in FPN 12 
;
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From the human homologue of this substitution is L170F. In humans, disease associated mutations of the SLC40A1 gene discovered to date are Y64N 15 , A77D 16 , N144D 17 , N144H 18 , N144T 19 , V162 [20] [21] [22] , Q248H 23, 24 , C326Y 25 and G490D 26 in iron overload patients, and N174I, Q182H and G323V in hyperferritinaemia patients 27 . Ferroportin disease patients often have high serum ferritin despite normal transferrin saturation (at least in early stages of disease) and iron deposits principally in the liver macrophages, but also in some cases in the hepatocytes [15] [16] [17] [18] [19] [20] [21] [22] [23] 25, 26, 28 . Patients often have a borderline anemia, and these cases do not respond well to phlebotomy 26, 29 .
FPN mutations exert their disease phenotype in an autosomal dominant fashion, but it is unclear how mutations in FPN lead to hemochromatosis. The expression of the protein on macrophages and predominant loading of iron in these cells in patients with A77D and V162 mutations suggests a loss of function and haploinsufficiency model 16, 30 . In this scenario, one wt and one dysfunctional mutated FPN are able to mediate iron absorption through the enterocyte, but cannot meet the much greater demands of iron recycling from red blood cells by macrophages.
Consequently, iron trapped in the macrophages leads to insufficient iron availability for erythropoiesis, and the bone marrow signals to the intestine to upregulate absorption. An alternative possibility is a dominant negative effect, where the incorporation of mutant proteins in a membrane could disrupt the function of the wild type.
A second model for how mutations could cause disease is a gain of function model, whereby overactive FPN leads to inappropriately high transport of iron from the diet through the gut enterocytes, resulting in an iron overload phenotype, particularly observed in patients who have mutations at N144 17, 18 and C326Y 25 . In contrast to the aforementioned loss of function patients, these patients tend to have high transferrin saturation and high serum ferritin, and on liver biopsy, iron is found throughout the tissue, not just confined to the macrophages 17, 18 (Merryweather-Clarke et al, manuscript in preparation).
We report that transfection of human wtFPN into a human epithelial cell line results in surface expression of the protein and causes an 
Maintenance and transfection of 293T cells.
The human kidney epithelial line 293T was maintained in Dulbecco's Modified Eagle's medium containing 10% fetal calf serum (Sigma). The day before transfection flasks/plates were seeded at 50% confluency. Cells were transfected using Effectene (Qiagen, Crawley, UK) following manufacturer's standard protocol. This gave 80-100% efficiency with a plasmid encoding green fluorescent protein.
Ferritin ELISA
Total cellular ferritin was measured from cell lysates using ferritin ELISA kits obtained from Laguna Scientific (Laguna Niguel, CA). Cells were transfected as above, in the presence or absence of 1mg/ml human holo transferrin (hTf) (Sigma). After culturing for 3 days, the cells were lysed in 0.5% NP-40 buffer (containing 50mM trizma base, 5mM EDTA and 150mM sodium chloride) at 2x10 7 cells /ml. Protein content of lysates was measured using the Bradford assay (Bio-Rad, Hercules, CA), and normalized by diluting with lysis buffer as necessary. Doubling dilutions were made, and 20µl of these were used per well in the ferritin ELISA. Each dilution was tested in triplicate, and compared against ferritin standards provided at 0, 15, 80, 250, 500, 1000ng/ml. These gave a linear range between 15-250ng/ml and so dilutions resulting in values within this range were used to calculate ng ferritin per 10 7 cells. It was generally found that hTf was required in the media to increase cellular ferritin levels to the linear range, as 293T cells naturally express low levels of ferritin.
FACS staining
Cells were tested for surface expression of TfR1 by flow cytometry as described previously Figure 1 to lose the wtFPN effect of upregulating TfR1 and down-regulating ferritin were shown in this assay to have no effect in reducing iron accumulation. However, mutants C326Y, N144H, N144D and Y64N which retain the wt effect, were shown to accumulate lower levels of iron, similar to wild type.
We then looked at iron release from the cells over 36 hours ( Figure 2C and D). In contrast, both A77D and V162 have a predominant intracellular localization (arrows in e, f, h, i) with little or no visible surface membrane staining, while the co-expressed wtFPN is still present at the cell membrane (arrow in g). This shows that neither of these two mutants interferes with the trafficking of the wtFPN to the cell surface. C326Y, which retains export function, is localized to the cell membrane (arrows in k) in the same way as wtFPN, and the merge shows they co-localize there (arrows in i).
Mutant forms of FPN do not bind to or reduce the function of wild type protein
The previous immunofluorescence implied that wtFPN and mutant FPN may not physically interact in the cell, but we wished to confirm this, because a possible dominant mechanism of action of the mutant FPNs in causing disease would be to bind to and inhibit wild type ferroportin. First, to test if wtFPN multimerizes we transfected 293T cells with wtFPN-c-Myc and wtFPN-FLAG, and as a control we also transfected cells with CD8 and wtFPN-FLAG ( Figure 4A ). Cells were lysed and proteins immunoprecipitated with monoclonal antibodies anti-CD8, anti-c-Myc, anti-FLAG or polyclonal anti-FPN-ct antibody. The precipitates were run on a gel, blotted and the membrane probed with anti-FLAG-HRP conjugate to look for evidence of coprecipitation. Figure 4A shows that the positive control anti-FLAG precipitate was detected as a protein band of around 67kDa, and this was also present in lysates precipitated with anti-FPN polyclonal serum but was much fainter. 
Discussion
The plethora of papers describing patients with iron overload linked to ferroportin mutations indicates its important role in iron metabolism. We have investigated how these mutations could lead to disease by in vitro expression of the protein. Firstly, we have shown that human wtFPN expressed in human cells is able to export iron, leading to an iron-deficient phenotype characterized by low ferritin and high TfR1 (Figure 1 and 2) . This extends the initial functional characterization of murine Fpn expressed in Xenopus oocytes and human cells [10] [11] [12] . In our experiments human FPN exported iron independently of added ceruloplasmin (data not shown); this could be due to ceruloplasmin present in fetal calf serum, or oxidases endogenous to the cell. Figure   3A and B), possibly due to protein misfolding leading to inefficient transport to the plasma membrane. However, Y64N, N144H, N144D, Q248H and C326Y are expressed on the cell surface as efficiently as wildtype and are able to export iron to a similar degree (Figures 1-3) . This leads to the suggestion that Figures 3B and 4B) , and the mutants do not interfere with the function of the wild type when co-expressed ( Figure 4C ). This leads us to conclude that the loss of function mutants cause disease by haploinsufficiency.
These results with the A77D, V162 and G490D mutations of FPN are thus consistent with the scheme proposed by Montosi and colleagues, to explain the macrophage iron loading observed in hemochromatosis patients with these mutations 16, 30 . The reduced iron export resulting from half the expressed molecules being nonfunctional leads to iron becoming trapped within macrophages that normally mediate ~30mg/day of iron recycling.
Enterocytes that take up ~1mg/ml of iron from the diet may be able to function adequately with one wild type allele of SLC40A1. Lower serum iron resulting from iron sequestration in macrophages reduces availability to the bone marrow for erythropoiesis. Thus it might be expected that these FPN mutations would lead to anemia, and indeed it has been reported that some patients are mildly anemic in the early stages of disease and respond poorly to phlebotomy 26, 29 ; in addition the L170F mutation that behaves like A77D, V162 and G490D in our assays, causes anemia in weh zebrafish 12 . In humans with A77D, V162 and G490D mutations, eventual iron overload may be a consequence of the erythron signaling to the gut enterocyte to increase iron uptake from the diet in order to compensate for the anemia. One corollary of this interpretation is that inactivation of one allele of Slc40a1 by gene knock-out should give a similar phenotype to the mutations, through reduced levels of expression of Fpn in the macrophages.
In contrast to A77D, V162 and G490D, in our assays mutations at Y64N, N144H, N144D, Q248H and C326Y all allow the full export function of FPN ( Figure 2) . The Q248H mutation has been found in overload patients but is also relatively common in African and African American populations with or without symptoms of overload 23, 28 . This suggests that Q248H may be a 
